Cognition Therapeutics Shares Tumble 29% as $30M Raise Fuels Phase 3 Zervimesine Push

Company Overview

Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company headquartered in Purchase, New York. Founded in 2007, the firm specializes in small-molecule therapeutics designed to target oligomeric toxic proteins implicated in neurodegenerative disorders such as Alzheimer’s disease and dementia with Lewy bodies. As of September 15, 2025, CGTX shares traded on the Nasdaq Capital Market at $1.5350, reflecting a 29.26% decrease on a volume of 7,316,478 shares.

Corporate Structure and Experience

Cognition Therapeutics operates with 11–50 employees, drawing expertise from neuroscience research, drug development, and clinical trial management. The company collaborates with the Alzheimer’s Clinical Trials Consortium (ACTC) and receives grant support from the National Institute on Aging (NIA) at the National Institutes of Health.

Neurodegenerative Research by Milad Fakurian

Recent Developments and News

• December 18, 2024: Topline results from the Phase 2 SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies showed improvement in behavioral, functional, cognitive, and movement measures.
• July 9, 2025: The U.S. Food and Drug Administration confirmed that the proposed Phase 3 program design for zervimesine in Alzheimer’s disease may support a New Drug Application.
• August 7, 2025: Q2 2025 financial results were released, noting milestones including 50% enrollment in the START study and the initiation of an expanded access program for trial participants with dementia with Lewy bodies (DLB).
• August 27, 2025: A registered direct offering of 14,700,000 shares to two institutional investors generated approximately $30 million in gross proceeds, designated for Phase 3 preparations and general corporate purposes.
• August 2025: At the Alzheimer’s Association International Conference 2025, data from the Phase 2 SHINE and START studies were presented. The START trial, which aims to enroll approximately 540 individuals with mild cognitive impairment and early Alzheimer’s disease, reached 75% enrollment.

Financial and Strategic Analysis

Cognition Therapeutics reported $10.74 million in cash and equivalents as of June 30, 2025, with total debt at 6.66% of equity. For the twelve months ending June 30, 2025, the company recorded a net loss of $32.99 million and negative levered free cash flow of $31.93 million. The August 2025 offering is expected to yield net proceeds of around $28.2 million after expenses.

The mechanism of zervimesine involves binding the sigma-2 receptor to displace toxic oligomers, which differs from antibody and enzyme-targeted approaches. Upcoming tasks include finalizing Phase 3 trial protocols, ensuring regulatory alignment on endpoints, and integrating biomarker findings into clinical design.

Market Position and Industry Context

Cognition Therapeutics operates within the biotechnology industry, focusing on neurodegenerative diseases that present significant unmet medical needs. Alzheimer’s disease and dementia with Lewy bodies affect millions globally, and approved treatments primarily provide symptomatic relief rather than disease modification. The competitive landscape includes large pharmaceutical firms developing monoclonal antibodies against amyloid and tau, as well as smaller biotech companies pursuing small-molecule and gene-therapy options. Cognition’s approach targeting the sigma-2 receptor presents a novel mechanism, but robust Phase 3 data will be necessary to establish clinical differentiation.

tl;dr

On September 15, 2025, Cognition Therapeutics (NASDAQ: CGTX) closed at $1.5350, a decrease of 29.26%. The company raised $30 million in a direct offering on August 27, 2025, to fund Phase 3 preparations for its lead candidate, zervimesine. Following an FDA end-of-Phase 2 meeting on July 9, 2025, the START trial reached 75% enrollment by August 2025. Key upcoming milestones include the initiation of Phase 3 trials and further analyses of biomarker data from previous Phase 2 studies.